Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Public ClinicalTrials.gov record NCT01799889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies. Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia \[LPL/WM\], small lymphocytic lymphoma \[SLL\], or marginal zone lymphoma \[MZL\]).
Study identification
- NCT ID
- NCT01799889
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 326 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2013 (Actual)
- Primary completion
- Sep 14, 2017 (Actual)
- Completion
- Jan 30, 2020 (Actual)
- Last update posted
- Nov 19, 2020
2013 – 2020
United States locations
- U.S. sites
- 46
- U.S. states
- 26
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Arizona Oncology Associates | Tucson | Arizona | 85710 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Rocky Mountain Cancer Centers, LLP | Boulder | Colorado | 80303 | — |
| Kaiser Permanente of Colorado | Denver | Colorado | 80218 | — |
| Cancer Center of Central Connecticut | Southington | Connecticut | 06489 | — |
| Florida Cancer - Colonial | Fort Myers | Florida | 33905 | — |
| Memorial Cancer Institute | Hollywood | Florida | 33021 | — |
| Ocala Oncology Center | Ocala | Florida | 34471 | — |
| Northside Hospital | Atlanta | Georgia | 30341 | — |
| Gwinnett Hospital System Dba The Center for Cancer Care | Lawrenceville | Georgia | 30046 | — |
| Northwest Georgia Oncology Center | Marietta | Georgia | 30060 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Illinois Cancer Specialists | Niles | Illinois | 60714 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Hematology Oncology Clinic, PLLC | Baton Rouge | Louisiana | 70809 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Minnesota Oncology Hematology, PA | Minneapolis | Minnesota | 55404 | — |
| Hattiesburg Clinic | Hattiesburg | Mississippi | 39401 | — |
| Oncology Hematology West PC dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| One Medical Center Drive | Lebanon | New Hampshire | 03756 | — |
| Summit Medical Group, P.A. | Florham Park | New Jersey | 07932 | — |
| Clinical Research Alliance | New York | New York | 10021 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Williamette Valley Cancer Center and Research Institute | Springfield | Oregon | 97477 | — |
| Prairie Lakes Health Care System, Inc. | Watertown | South Dakota | 57201 | — |
| Jones Clinic PC | Germantown | Tennessee | 38138 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Austin Midtown | Austin | Texas | 78705 | — |
| Texas Oncology-Medical City Dallas | Dallas | Texas | 75230 | — |
| Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Cancer Care Network of South Texas | San Antonio | Texas | 78217 | — |
| Cancer Care Center of South Texas | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23226 | — |
| Columbia Basin Hematology and Oncology | Kennewick | Washington | 99336 | — |
| University of Washington | Seattle | Washington | 98109 | — |
| Northwest Cancer Specialists, PC | Vancouver | Washington | 98684 | — |
| Yakima Valley Memorial Hospital North Star Lodge | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01799889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2020 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01799889 live on ClinicalTrials.gov.